N -Phenyl-1-(phenylsulfonyl)-1 H -1,2,4-triazol-3-amine as a New Class of HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.2c02055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Thomas Lane und 12 weiteren Autor:innen. Beteiligte Einrichtung: Collaborations Pharmaceuticals Inc., 840 Main Campus Drive, Lab 3510, Raleigh, North Carolina 27606, United States. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV-1, HIV Infections. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NINDS NIH HHS, NIEHS NIH HHS.
Abstract (Originalsprache)
Highly active antiretroviral therapy (HAART) has revolutionized human immunodeficiency virus (HIV) healthcare, turning it from a terminal to a potentially chronic disease, although some patients can develop severe comorbidities. These include neurological complications, such as HIV-associated neurocognitive disorders (HAND), which result in cognitive and/or motor function symptoms. We now describe the discovery, synthesis, and evaluation of a new class of N-phenyl-1-(phenylsulfonyl)-1H-1,2,4-triazol-3-amine HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTI) aimed at avoiding HAND. The most promising molecule, 12126065, exhibited antiviral activity against wild-type HIV-1 in TZM cells (EC50 = 0.24 nM) with low in vitro cytotoxicity (CC50 = 4.8 μM) as well as retained activity against clinically relevant HIV mutants. 12126065 also demonstrated no in vivo acute or subacute toxicity, good in vivo brain penetration, and minimal neurotoxicity in mouse neurons up to 10 μM, with a 50% toxicity concentration (TC50) of >100 μM, well below its EC50.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Collaborations Pharmaceuticals Inc., 840 Main Campus Drive, Lab 3510, Raleigh, North Carolina 27606, United States.
- Research Center of Biotechnology RAS, Leninsky Prospekt 33-2, 119071, Moscow 119071, Russia.
- Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
- Department of Neurology, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
- Department of Biomedical Science, University of Cagliari, Monserrato 09042, Italy.
ORCID-Profile: Thomas Lane, Sean Ekins
Förderung
- NIAID NIH HHS
- NINDS NIH HHS
- NIEHS NIH HHS
- NIGMS NIH HHS
- National Institute of Environmental Health Sciences
- National Institute of Neurological Disorders and Stroke
- Center for AIDS Research, University of North Carolina at Chapel Hill
- National Institute of General Medical Sciences
Zitieren
APA
Lane, T., Makarov, V., Nelson, J. A. E., Meeker, R. B., Sanna, G., Riabova, O., Kazakova, E., Monakhova, N., Tsedilin, A., Urbina, F., Jones, T., Suchy, A., & Ekins, S. (2023). N -Phenyl-1-(phenylsulfonyl)-1 H -1,2,4-triazol-3-amine as a New Class of HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c02055
Vancouver
Lane T, Makarov V, Nelson JAE, Meeker RB, Sanna G, Riabova O, et al. N -Phenyl-1-(phenylsulfonyl)-1 H -1,2,4-triazol-3-amine as a New Class of HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.2c02055
BibTeX
@article{Lane2023,
author = {Lane, Thomas and Makarov, Vadim and Nelson, Julie A E and Meeker, Rick B and Sanna, Giuseppina and Riabova, Olga and Kazakova, Elena and Monakhova, Natalia and Tsedilin, Andrey and Urbina, Fabio and Jones, Thane and Suchy, Ashley and Ekins, Sean},
title = {N -Phenyl-1-(phenylsulfonyl)-1 H -1,2,4-triazol-3-amine as a New Class of HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.2c02055}
}
EUVIMED